描述:Certepetide (CEND-1) 是一种双功能环肽 (又名 iRGD)。Certepetide 是一种可穿透肿瘤的多肽,其 RGD motif 可与 α-V 整联蛋白 ( alphav-integrins ) 相互作用,并激活神经纤毛蛋白 1 ( NRP-1 ),从而将实体瘤微环境转化为临时活性分子管道。Certepetide 可用于肿瘤中累积,可用于胰腺癌和其他实体瘤的研究。
单字母:Ac-CRGDKGPDC-CONH2(Disulfide Bridge:C1-C9)
多字母:Ac-Cys-Arg-Gly-Asp-Lys-Gly-Pro-Asp-Cys-CONH2(Disulfide Bridge:Cys1-Cys9)
氨基酸个数:9
分子式:C37H60O14N14S2
平均分子量(MW):989.09
精确分子量(Exact Mass)(MW):988.39
等电点(PI):9.81
pH=7.0时的净电荷数:1.94
GRAVY:-1.42
亲水残基比例:0.27
消光系数:-
溶解建议:亲水
参考文献:
[1]. International Nonproprietary Names for Pharmaceutical Substances (INN). WHO Drug Information, Vol. 36, No. 2, 2022
[2]. Ruoslahti Erkki, et al. Methods for treating pancreatic cancer and other solid tumors. WO2021226148.
[3]. Andrew Peter Dean, et al. Updated single institution outcome data from the first-in-human CEND-1 trial in metastatic pancreatic cancer. Journal of Clinical Oncology 2021 39:15_suppl, e16274-e16274
[4]. Harri A Järveläinen, et al. Assessment of the Pharmacokinetics, Disposition, and Duration of Action of the Tumour-Targeting Peptide CEND-1. Int J Mol Sci. 2023 Mar 16;24(6):5700.